ESTRO 2024 - Abstract Book

S2455

Clinical - Urology

ESTRO 2024

Intraprostatic recurrences after radiotherapy of intermediate and high-risk prostate cancer patients appeared almost always at the location of the primary GTV, and mainly in patients not receiving a substantial focal boost. This emphasizes the importance of an adequate identification of the GTV and the delivery of a high boost dose, and suggests there is a room for de-escalation of the dose to the remaining prostate gland, which in combination might further reduce radiation induced toxicity while maintaining a high local control.

Keywords: intraprostatic recurrence, focal boosting

References:

1. Kerkmeijer LGW, Groen VH, Pos FJ, Haustermans K, Monninkhof EM, Smeenk RJ, Kunze-Busch M, de Boer JCJ, van der Voort van Zijp J, van Vulpen M, Draulans C, van den Bergh L, Isebaert S, van der Heide UA. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. J Clin Oncol. 2021 Mar 1;39(7):787-796. doi: 10.1200/JCO.20.02873. 2. Pucar D, Hricak H, Shukla-Dave A, Kuroiwa K, Drobnjak M, Eastham J, Scardino PT, Zelefsky MJ. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):62-9. doi: 10.1016/j.ijrobp.2007.03.065. 3. Arrayeh E, Westphalen AC, Kurhanewicz J, Roach M 3rd, Jung AJ, Carroll PR, Coakley FV. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):e787-93. doi: 10.1016/j.ijrobp.2011.11.030. 4. Gorovets D, Wibmer AG, Moore A, Lobaugh S, Zhang Z, Kollmeier M, McBride S, Zelefsky MJ. Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion. Eur Urol Oncol. 2023 Jun;6(3):275-281. doi: 10.1016/j.euo.2022.02.005.

1794

Proffered Paper

Short ADT + SBRT improves outcomes in oligorecurrent hormone-sensitive PCa: result of RADIOSA trial

Giulia Marvaso 1 , Giulia Corrao 2 , Mattia Zaffaroni 2 , Maria Giulia Vincini 2 , Chiara Lorubbio 2 , Sara Gandini 2 , Francesco Alessandro Mistretta 3 , Stefano Luzzago 3 , Dario Zerini 2 , Gennaro Musi 3 , Sara Alessi 4 , Cristiana Fodor 2 , Giuseppe Petralia 4 , Gabriella Pravettoni 2 , Ottavio De Cobelli 3 , Roberto Orecchia 5 , Barbara Alicja Jereczek-Fossa 2 1 Milan, Milan, Milan, Italy. 2 IEO, European Institute of Oncology IRCCS, Milan, Italy, Division of Radiation Oncology, Milan, Italy. 3 IEO, European Institute of Oncology IRCCS, Milan, Italy, Division of Urology, Milan, Italy. 4 IEO, European Institute of Oncology IRCCS, Milan, Italy, Division of Radiology, Milan, Italy. 5 IEO, European Institute of Oncology IRCCS, Milan, Italy, Scientific Directorate, Milan, Italy